Document:

Exhibit 10.102 

AMENDMENT

 

This AMENDMENT effective as of December
28, 2012 (this "Amendment"), by and among Timothy and Thomas LLC (the "Holder"), and VG Life Sciences Inc. formally
known as Viral Genetics, Inc. a Delaware corporation (the "Company").

 

The Holder and the Company are parties
to a Convertible Debenture (See attached schedule "A") made the 19th day of October 2010 (the "Agreement"),
and the Holder and the Company desire to amend and modify the Agreement as provided for in this Amendment. See attached schedule
A3

 

The Holder and the Company realize that
an orderly liquidation of the debenture will have a maximum beneficial effect on both parties.

 

NOW THEREFORE, for good and valuable consideration,
the receipt and legal adequacy of which is hereby acknowledged, it is agreed as follows:

 

1.Capitalized Terms. Capitalized
terms used in this Amendment which are not defined herein shall have the same meanings herein as are ascribed to such terms in
the Agreement.

 

2.Principal. Section 3 of the
Agreement is amended to provide that the remaining Tranches of the Note shall be paid as follows:

 

Pursuant to attached schedule "B"

 

3.Effect. Except as expressly
amended hereby, the Agreement shall remain in full force and effect in accordance with its terms.

 

 

IN WITNESS WHEREOF, the parties have executed
this Amendment as of the date first above written.

 

Timothy and Thomas, LLC

 

By:   /s/ Timothy Wright

Duly Authorized
Officer

 

 

VG Life Sciences

A Delaware corporation

 

By: /s/ Haig Keledjian

Duly Authorized
Officer 

 

 

    	1

    	 

    

 

SCHEDULE B

 

Release
schedule base on stock price

 

Amount of convertible debt remaining under the

 

Agreement     $ 862,500.00

 

Price per share is defined as 15 day weighted average at closing.

 

Mandatory quarterly conversion if price per share is $1.00 is
$50,000.00 or greater as mutual agreed upon by the parties.

 

Mandatory quarterly conversion if price per share is $2.00 is
$75,000.00 or greater as mutual agreed upon by the parties.

 

All other term as to price, definitions, terms and option stay
the same. This schedule only effects the liquidation of the debt.

 

If the price is below a dollar then note is convertible 01/01/2020Exhibit 10.103

 

CONSULTING
SERVICES AGREEMENT - Addendum

 

THIS
ADDENDUM to the CONSULTING SERVICES AGREEMENT (the “Agreement”), executed on the date signed below, is effective
as of January 1, 2012, and is entered into by and between VG Life Sciences Inc. (formerly Viral Genetics, Inc.) a Delaware corporation
with its executive office located at 2290 Huntington Drive, Suite 100, San Marino, California 91108 (the “Company”),
and JTL Enterprises Corp, a New York corporation with its executive offices located at 1107 38th Avenue, Seattle, WA 98122 (“Consultant”).
The terms “Party” and “Parties” refer to the Company, VG Energy, Inc. and Consultant individually
and collectively.

 

Whereas
the Parties have agreed to certain modifications with respect to compensation arrangements to be effective on
commencement of this agreement; and

 

Whereas
it is the intention of the Parties that all the terms and conditions included in the Consulting Agreement to which
this addendum shall be attached shall apply to this Addendum as if it were part of the agreement, unless specifically
modified below.

 

Therefore
the parties hereto for good and valuable consideration agree to the following modifications to the original paragraphs:

 

2.
Fees and Expenses. Attachment A Modified, which is incorporated herein, is a summary of these fees which shall be earned
monthly as indicated for each of the 12 months in the period ending December 31, 2012, payable in cash and shares of common stock
of the Company and VG Energy. Consultant shall earn and be fully vested in all fees and common shares as services are billed and
rendered monthly. Shares of VGLS have been determined utilitizing a price of $0.20 per share of VGLS after giving effect to the
6600:1 reverse split and $0.83 per share of VG Energy.

 

Consultant
may elect, at Consultant’s sole option, to accept restricted shares of the Company and/or VG Energy and common
stock purchase warrants in lieu of cash payments based upon a terms and conditions agreed to by the parties hereto. In that
event, the Company shall cause certificates and appropriate warrants to be issued within 10 days of notice by Consultant
of conversion of delinquent payments.

 

The
Company acknowledges that it is indebted to Consultant for fees related to Services rendered in 2011 pursuant to
the proceeding Consulting Services Agreement dated February 9, 2011 and amended June 30, 2011 in the amoun t of $13,750.
Further, all cash compensation and stock based compensation for services pursuant to this agreement are currently due
and payable.

 

IN
WITNESS WHEREOF, and intending to be legally bound, this Addendum shall be considered as part of the Consulting
Agreement between the parties which was effective as of January 1, 2012, an executed copy of which is attached, has been
executed by the Company and Consultant effective as of the date first written above.

 

VG
Life Sciences Inc. (formerly Viral Genetics, Inc.)

 

By:
/s/ Haig Keledjian   Date: December 31, 2012

Name
and Title: Haig Keledjian, President

 

 

 

JTL
Enterprises Corp.

 

By:
/s/ Myron W. Landin   Date: December 31, 2012

Name
and Title: Myron W. Landin, President

 

 

    	1Exhibit 10.104

 

AMENDED AND
RESTATED AMENDMENT TO CONVERTIBLE DEBENTURES

 

AMENDMENT AND RESTATED AMENDMENT TO CONVERTIBLE
DEBENTURES effective January 1st, 2013 (this "Amendment"), to the various Convertible Debentures attached
hereto as Exhibit A (collectively, the "Debentures"), by and between VG LIFE SCIENCES INC., a Delaware corporation formally
known as Viral Genetics Inc. (the "Company") to DMBM, Inc.. a New York corporation ("DMBM").

 

This Amendment
shall clarify certain vagueness in the original Amendment to reflect the understanding and agreement between the Company and DMBM.
This Amendment shall amend and restate in its entirety that certain Amendment to Convertible Debentures dated as of September 14,
2012 (the "Original Amendment") between the Company and DMBM.

 

All
of the indebtedness represented by the Debentures remains unpaid and at present the Company does not have sufficient cash or other
liquid assets to pay the Notes as they come due and payable. As of this date certain of the Debentures are past due. The Company
intends to seek financing in the near future from institutional investors and the overhang of unpaid debt represented by the Debentures
will adversely affect the Company's ability to successfully complete that financing. The ability of the holder of the Debentures
to demand repayment of the Debentures in cash will also adversely affect the Company's ability to complete any such financing.

 

Therefore,
in order to induce DMBM to convert the Debentures into shares of the Company's common stock (the "Common Stock"), the
Company and DMBM are entering into this Amendment

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and legal adequacy of which is hereby acknowledged by the parties,
the Company and DMBM hereby agree as follows:

 

1.            Terms.
Capitalized. terms used in this Amendment shall have the same meanings herein as are given to such terms in the Debenture, unless
otherwise expressly defined herein.

 

2.            Amendment
of Conversion Price. Notwithstanding anything set forth in the Debentures, the Conversion Price of each of the Debentures
is amended to the lower of (a) the Conversion Price set forth on the fourth column of Exhibit A attached hereto or (b) a discount
of thirty percent (30%) from the average of the closing price of the Company's Common Stock (on the principal exchange or market
in which the Company's Common Stock trades) for the fourteen (14) trading days prior to DMBM's submission of a conversion notice
to the Company.

 

3.            Amendment
to Payment in Cash. Notwithstanding anything set forth in the Debentures, the Debentures are hereby amended to eliminate the
right of DMBM to demand or request repayment of the Debentures in cash. DMBM acknowledges it is releasing the Company from any
obligation to pay the Debentures in cash.

 

    	1

    	 

    

 

4.            Waivers.
In consideration of the reduction of the Conversion Price as provided for this Amendment, DMBM waives accrued interest and the
right to receive interest on the Debentures and any other defaults under the Debentures.

 

5.            Warrants.
In consideration of this Amendment, the company will issue the following Warrants (collectively, "the Warrants") to
purchase shares of Common Stock to DMBM:

1,171,428 Warrants exercisable at $.50 per
share;

1,171,428 Warrants exercisable at $1.00 per share;

1,171,428 Warrants exercisable at $1.50 per share;

1,171,428 Warrants
exercisable at $2.00 per share.

 

The Warrants will have a
cashless exercise option, shall have a term of five (5) years and shall have such other terms and provisions as are customary for
Warrants of this nature.

 

6.            Governing
Law. Except as expressly amended hereby. the Debentures shall remain in full force and effect in accordance with its terms.
This Amendment shall be governed by and construed and enforced in accordance with the laws of the State of New York, without regard
or reference to any of its choice of laws or conflicts of laws principles which would require or permit the application of the
laws of another jurisdiction.

 

7.            Drafting
History. In: resolving any dispute or controversy arising out. of or relating to this Amendment or in connection with construing
any term or provision in this Amendment, there shall be no presumption made or inference drawn because of the inclusion of a provision
not contained in a prior draft or the deletion of a provision contained in a prior draft. The parties acknowledge and agree that
this Amendment was negotiated and drafted with each party being represented by competent legal counsel of its choice and with
each party having an opportunity to participate in the drafting of the provisions hereof and shall therefore this Amendment shall
be construed and interpreted as if drafted jointly by the parties and not with any presumption against either of the parties.

 

8.            Assignment.
This Amendment may not be assigned by either party nor may a party's duties or obligations hereunder be delegated without the
prior written consent of the other party. This Amendment shall inure to the benefit of, and shall be binding upon, the parties,
their respective successors (whether by merger or consolidation, recapitalization or other similar transaction) and their permitted
assignees.

 

9.            Complete
Amendment. This Amendment and the Debentures constitutes the entire understanding and agreement of the parties with respect
to the subject matter hereof, and it supersedes all prior and/or contemporaneous understandings and agreements among the parties,
whether oral or written, with. respect to such subject matter, all of which are merged herein. There are no representations, warranties,
agreements or promises between the parties with respect to such subject matter, except those, which are expressly set forth herein.
The Original Amendment shall be merged herein as it is hereby amended, restated and replaced in its entirety by this Amendment.

 

    	2

    	 

    

 

10.            Headings,
Counterparts. The section head ins contained in this Amendment are inserted herein for the purpose of convenience and reference
only and they are not to be given any substantive effect, nor shall they be used or have any effect upon the construction or interpretation
of any term or provision hereof. Any reference to the masculine, feminine or neuter gender shall be a reference to such other
gender as if appropriate. References to the singular shall include the plural and vice versa. This Amendment shall be effective
when duly executed counterparts are executed and delivered by each of the parties. This Amendment may be executed in multiple
counterpart's (and may be executed by facsimile. PDF or electronic signature. Which shall constitute a legal and valid signature
for purposes hereof), each of which shall constitute an original, and all of which, when taken together, shall constitute one
and the same document. The parties acknowledge and agree that this Amendment is effective as of its specified date regardless
of the fact that it is being executed by either of the parties on another date (including a later date). Facsimile or PDF counterparts
of this Amendment shall be deemed to be considered original and valid counterparts hereof.

 

IN WITNESS WHEREOF, each of the parties
has executed this Amended and Restated Amendment to Convertible Debentures, effective as of the date first written above.

 

 

VG
LIFE SCIENCES, INC.

 

 

By:
/s/ Haig Keledjian

       Name: Haig Keledjian

       Title: President & CEO

 

 

 

 

DMBM,
INC.

 

 

By:
/s/ Damon R Devitt

       Name:
Damon R Devitt

       Title:
President, DMBM Inc.

 

 

 

 

    	3

    	 

    

 

EXHIBIT
A

 

	 	 	Price
    as	Market	 	 
	Date	Amount	a
    % market	Price	pps	#
    shares
	November	$42,000.00	0.50000	0.28000	0.140000	300,000.00
	December	$64,000.00	0.50000	0.28000	0.140000	457,142.86
	January	$73,000.00	0.55000	0.28000	0.154000	474,025.97
	February	$137,000.00	0.75000	0.8000	0.210000	652,380.95
	March	$152,000.00	0.75000	0.28000	0.210000	723,809.52
	April	$80,000.00	0.75000	0.28000	0.210000	380,952.38
	May	$99,000.00	0.75000	0.28000	0.210000	471,428.57
	June	$84,000.00	0.75000	0.28000	0.210000	400,000.00
	July	$39,500.00	0.75000	0.28000	0.210000	188,095.24
	August	$1,000.00	0.75000	0.28000	0.210000	4,761.90
	September	$54,000.00	0.75000	0.28000	0.210000	257,142.85
	October	 $1,000,00	0.75000	0.28000	0.210000	71,428.57
	November	$15,000.00	0.75000	0.28000	0.210000	71,428.57
	December	 $2,500.00	0.75000	0.28000	0.210000	97,619.05
	 	 	 	 	 	 
	 	$
    76,000.00	0.70000	 	0.192518	4,550,216.45

 

 

 

    	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]